Wound closure preparation on the basis of natural raw materials

Abstract

The present invention relates to a wound closure preparation made of nature-based raw materials, in particular to a sprayable bio-based wound closure preparation that contains viscose fibers and can be applied with the aid of a tube.

Description

[0001] Wound closure preparation based on natural raw materials

[0002] The present invention relates to a wound closure preparation made from natural-based raw materials, in particular a liquid, gel, or paste-like preparation containing a fiber content. Application is advantageously by spraying or from a tube.

[0003] Wound closure preparations are usually liquid agents that are applied to a wound and close it.

[0004] Liquid bandages or liquid plasters are usually packaged in aerosol containers with a propellant. These are commercially known as wound dressing sprays, which can be sprayed onto the wound by pressing the valve button.

[0005] It is also possible to apply wound closure preparations using a pump sprayer, but this method of application is less uniform than when applied as an aerosol due to the pump strokes.

[0006] Commercial wound closure agents include Hansaplast, Wundmed, GooFix, and IIRGO spray plasters. They are based on polyurethane systems, acrylate systems, and / or nitrocellulose and do not contain any fiber components.

[0007] Wound closure preparations and the wound closure films formed from them cover the wound without the use of additional agents and promote healing. However, wound closure films are generally not particularly resistant to mechanical stress, so contact with clothing, for example, can lead to abrasion of the wound closure film.

[0008] To prevent abrasion or tearing of the wound closure film, it may be beneficial to protect the wound covered with the wound closure preparation with additional measures. Wound coverings such as bandages or plasters, which provide "mechanical" protection, are often used for this purpose. Furthermore, wound closure preparations can contain dispersed or cross-linkable polymers or hydrogels, which form a more stable and friction-resistant film on the wound. This further protects the wound from the penetration of dirt and microorganisms. Furthermore, such polymer films can be "adjusted" to allow the passage of water (vapor) or wound secretions. This has a positive effect on the healing process.

[0009] Application is usually done with a spatula, tube, or brush (wound balms, wound creams, and healing ointments), or contactless by spraying. Contactless application has the advantage that no additional germs enter the wound through the applicator, allowing large wounds—such as abrasions—to be treated more quickly.

[0010] After application and evaporation of the solvent contained in the wound closure preparation, a flexible film forms from the liquid wound closure preparation.

[0011] Film-forming, sprayable polymer solutions for the production of wound dressings (wound dressing sprays) are known from DE 2343923 A1. This is a sprayable, film-forming polymer solution that is applied in thin layers, primarily via an aerosol container, to cuts, abrasions, or surgical wounds to be dressed. After the solvent evaporates, a thin, coherent film forms, covering the wound.

[0012] Cellulose-based wound closure formulations are already known. In FR 3064488, the cellulose is present at a concentration of > 6%.

[0013] For the purposes of the invention, wounds are understood to mean skin lesions such as wounds, abrasions, vesicles, bullae, crusts, papules, nodules, ulcers or other skin irregularities.

[0014] Very high cellulose concentrations previously resulted in very stiff wound closure films with poor adhesion to the skin / wound. The invention overcomes this disadvantage by adding fibers and glycerin. This allows for more mechanically resilient films with long-lasting adhesive strengths, even at lower cellulose concentrations, compared to the prior art.

[0015] A preparation according to the invention contains a natural polymer, at least one natural vegetable oil, glycerin and a proportion of structuring natural fibers or fibers based on natural raw materials, i.e., no raw materials based on fossil raw materials, in a dermatologically acceptable solvent.

[0016] The wound closure preparation according to the invention comprises at least the following components: a) 0.3 - 14.7 wt.% of at least one natural polymer, b) 0.3 - 4.2 wt.% glycerol, c) 0.3 - 34.7 wt.% of at least one vegetable oil, d) 0.1 - 13.7 wt.% structuring fibers, e) one or more dermatologically acceptable solvents, whereby the wt.% (weight percent) refers to the entire wound closure preparation as a solution / suspension without optionally used propellants or other application aids. This concentration is referred to below as wt.% (addition).

[0017] The preparation components are dissolved or suspended in a dermatologically harmless solvent.

[0018] By varying the solvent quantity, the viscosity of the solution / suspension can be adjusted. A high solvent quantity results in a low-viscosity wound closure preparation, making it suitable for spraying, while a low solvent quantity results in a high-viscosity wound closure preparation, making it suitable for application from a tube, jar, or dispenser.

[0019] After the solvent evaporates, a wound closure film remains at the application site (wound and surrounding area). This special composition of the wound closure preparation results in very robust wound closure films compared to conventional wound closure films. This allows clothing to be worn over the wound closure preparation without abrasion. Furthermore, the resulting wound closure film can be removed as a peel-off film, similar to a normal bandage.

[0020] According to the invention, in addition to these main components, additional excipients may be included, such as pharmaceutical active ingredients that support wound healing and / or microbicides that counteract contamination.

[0021] Possible excipients can be: antibacterial agents, such as antimicrobial peptides, cationic polymers or cationic molecules (octenidine, PHMB, etc.), wound healing-promoting agents such as mRNA, hyaluronic acid, anti-inflammatory agents (lidokaine, etc.), scar-reducing agents, silicones or silicone-like substances, pain-relieving agents such as lidocaine or cannabinoids.

[0022] The natural polymer acts as a film former in the wound closure film. It embeds the fibers and holds them together. Preferred natural polymers according to the invention are, in particular, celluloses and cellulose derivatives, particularly preferably ethylcellulose, methylcellulose, hydroxypropyl methylcellulose, nitrocellulose, carboxymethylcellulose, gellan gum, xanthan gum, distarch phosphate, and sclerotium gum.

[0023] According to the invention, ethylcellulose is particularly preferred as a natural polymer.

[0024] A particularly good embodiment of the invention is a wound closure preparation containing ethylcellulose and / or ethylcellulose derivative in combination with castor oil, glycerin, viscose fibers and optionally sunflower oil.

[0025] Celluloses with a molecular weight of 100,000 to 500,000 g / mol are particularly advantageous.

[0026] Celluloses with a molecular weight of 150,000 to 250,000 g / mol are particularly advantageous.

[0027] The cellulose or cellulose derivative also ensures that wound secretions can be absorbed, thus hydrating the film ('hydration' of the wound closure film). This allows water to 'diffuse' through the wound closure film. The hydrated film can thus keep the wound moist but not wet, which can support wound healing.

[0028] Glycerin, as used herein, refers to technical-grade glycerin for the pharmaceutical industry and cosmetic applications. It may therefore contain the usual traces of water (maximum 0.5% by weight) that are inherent in the manufacturing process. Tests have shown that no differences in performance are achieved with the purest glycerin (analytical grade).

[0029] The proportion of castor oil increases the hydrophobic portion of the film formed, which leads to an increase in the adhesion of the film to the skin surface.

[0030] Castor oil in the sense of the invention is to be understood as purified castor oil as approved for cosmetic and / or medicinal purposes (density: 0.95 - 0.97 g / cm 3 ; viscosity: approx. 1000 mPas).

[0031] According to the invention, it is advantageous if the preparation, in addition to the castor oil content, also contains a lower content of a second vegetable oil, in particular sunflower oil. This additional vegetable oil ensures even greater water resistance of the film formed from the preparation on the skin.

[0032] According to the invention, the wound closure preparation contains a proportion of natural or synthetic fibers. The fibers usable according to the invention have a length between 0.1 and 0.4 mm and a fineness of 0.9 to 20 dtex.

[0033] According to the invention, viscose fibers or other fibers based on cellulose or cellulose derivatives such as acetate fibers, bamboo fibers, lyocell fibers or modal fibers are advantageously used as structural fibers.

[0034] Viscose is a regenerated fiber synthetically derived from cellulose, which gives it distinct properties. This distinguishes it from pure natural fibers, but its properties are similar to those of cotton. Despite the synthetic manufacturing process, viscose cannot be considered a synthetic fiber, as it is made from natural cellulose extracted from wood components. Viscose is often referred to colloquially as artificial silk.

[0035] According to the invention, a ratio of ethylcellulose to viscose fibers between 2.4 and 0.8, better between 1.5 and 1.2, is preferably chosen.

[0036] The fibers are suspended in the other ingredients and do not dissolve. Whether applied in the sprayable formulation or in the thick / paste-like formulation (applied from a jar / tube / dispenser), the resulting wound closure film is significantly more robust with the preferred ratio of natural polymer to fibers. It is advantageous to coat the fibers with a hydrophobic coating.

[0037] The viscose fibers advantageously have a length between 0.1 mm and 0.4 mm.

[0038] The viscose fibers advantageously have a fineness of 0.9 to 20 dtex.

[0039] The wound closure preparation according to the invention contains conventional organic solvents (biocompatible solvents) such as ethyl acetate, alcohol, and / or alkanes, which are highly volatile. In the case of a spray application form, the wound closure preparation also contains propellant.

[0040] These solvents generally pose no danger to the human body as long as they are applied topically. When selecting solvents, the benefit of wound closure must be weighed against the potential harm caused by the solvent. Some solvents, such as ethyl alcohol or isopropyl alcohol, already have an antiseptic effect, which can further enhance the benefits of the wound closure preparation.

[0041] A very good embodiment of the inventive wound closure preparation for application from tubes, syringes or drag piston dispensers consists of: a) 9.3 to 14.7% by weight of at least one ethylcellulose and / or ethylcellulose derivative, b) 11 to 21% by weight of castor oil, c) 6.3 to 13.7% by weight of sunflower oil, d) 1.8 to 4.2% by weight of glycerol, e) 4.7 to 13.7% by weight of viscose fibers, f) up to 66.9% by weight of one or more dermatologically acceptable solvents in which the preparation ingredients are dissolved / suspended g) optionally small amounts of pharmaceutical active ingredients and / or microbicides, wherein the wt.% (percent by weight) refers to the entire wound closure preparation as a solution / suspension.

[0042] The high ethylcellulose content of 9.3–14.7 wt% (Zub) prevents the viscose fibers from settling. Unlike an aerosol, it's not possible to mix the preparation by shaking in the tube. This makes the aforementioned cellulose content particularly suitable for application from the tube. Even application to the skin is guaranteed.

[0043] In the tube formula, the total oil content of up to 52% by weight based on the wound closure preparation without solvent is advantageous.

[0044] Another very good embodiment of the inventive wound closure preparation for aerosol application consists of: a) 0.8 to 4.2% by weight of at least one ethylcellulose and / or ethylcellulose derivative, b) 1.2 to 15.8% by weight of castor oil, c) 0.4 to 1.6% by weight of glycerol, d) 0.4 to 2.1% by weight of viscose fibers, e) up to 97.2% by weight of one or more dermatologically acceptable solvents in which the preparation components are dissolved / suspended f) optionally small amounts of pharmaceutical active ingredients and / or microbicides, wherein the wt.% (weight percent) refers to the entire wound closure preparation as a solution / suspension without propellant gas.

[0045] The fact that a smaller amount of cellulose / cellulose derivative of 0.8 - 4.2 wt.% (Zub) together with a smaller amount of viscose fibers of 0.4 - 2.1 wt.% (Zub) compared to a paste is sufficient for the sprayable formula can be explained by a synergistic effect due to the homogenizing / flexibilizing effect of the glycerin in the formulation according to the invention. This results in an optimal distribution of the viscose fibers in the film. The significantly more homogeneous distribution of the film increases the film's flexibility, which is also noticeable when worn on the skin. A wound closure film according to the invention adapts better to the skin, the film is not as taut as a prior art film, and the high flexibility of the film formed according to the invention also prevents tears in the film when worn on the skin / wound. The viscose fibers, in their specific ratio to the binder, lead to a rougher and more robust film surface.

[0046] Liquid dressing materials or liquid plasters are marketed in aerosol containers containing a propellant, known as wound dressing sprays, from which they can be sprayed onto the wound as needed by pressing the valve button. Spray plaster systems such as those described in patents DE 102021200975, DE 2343923, DE 2924042, and EP2196225 B1 are known.

[0047] In a sprayable wound closure preparation according to the invention, the total content of oils is not more than 67% by weight based on the wound closure preparation without solvent and propellant gas.

[0048] At this ratio, a pronounced hydrophobicity is developed, resulting in greater water repellency. This also provides protection against water and dirt from the outside.

[0049] Unexpectedly for the expert, the breathability of the film was not impaired when the viscose fibers were added compared to preparations without them, so the resulting films are very breathable. Due to the strong cohesion of the fibers within the film, the entire film can be peeled off. The viscose fibers create a rough and cloudy surface in the resulting wound closure film. This allows the wound closure film to be visually recognized, allowing its protective effect to be visually confirmed. The specific ratio of film former to viscose fibers allows the formation of a wound closure film that is robust enough for long-lasting protection and complete removal. At the same time, the film remains flexible enough so that it does not stretch or crack.

[0050] The main task of the preparation according to the invention and the wound closure film formed therefrom is a secure wound closure which prevents contamination of the wound and / or germ contamination of the wound.

[0051] The property of "secure wound closure" is often considered the most important feature of a plaster or similar product, but it is not always achievable. Depending on the fluid absorption capacity of the wound dressing and / or the adhesive, as well as the product's water vapor permeability, perspiration or sweating often lead to unwanted premature detachment from the skin.

[0052] A wound closure preparation according to the invention forms a 'breathable'

[0053] Wound closure film. This prevents it from peeling off automatically

[0054] Moisture accumulation is avoided. State-of-the-art technology

[0055] Wound closure materials known for their incorporated hydrogels

[0056] To buffer moisture accumulation and thereby prevent detachment and moist

[0057] To enable wound healing.

[0058] In wound closure films made from the wound closure preparation according to the invention, the incorporation of hydrogels for moisture regulation is not necessary.

[0059] Examples

[0060] The effect of the preparation according to the invention is illustrated by the following examples.

[0061] Table 1 shows a control formulation and two examples (A and B) for high-viscosity formulations for application from a tube containing a viscose fiber mix and a single viscose fiber type. Table 1:

[0062] The wearing comfort of sample preparations A and B was determined in a study (49 participants). The results are shown in Figure 4.

[0063] The preparations Example A and Example B each represent particularly preferred embodiments of the invention:

[0064] Wound closure preparation with uniform viscose fiber with 0.9 dtex / 300 pm for application from the tube comprising 12% ethylcellulose, 16.32 wt% ± 0.2 wt% castor oil, 11.20 wt% ± 0.2 wt% sunflower oil, 3.12 wt% ± 0.2 wt% glycerin, 8 wt% ± 0.2 wt% viscose fibers, 49.36 wt% ± 0.4 wt% ethanol.

[0065] Wound closure preparation with a viscose fiber mix from 0.9 dtex to 17 dtex;100 μm containing 12 wt% ± 0.2 wt% ethylcellulose, 16.32 wt% ± 0.2 wt% castor oil, 11.20 wt% ± 0.2 wt% sunflower oil, 3.12 wt% ± 0.2 wt% glycerol, 9.99 wt% ± 0.2 wt% viscose fibers, and 47.37 wt% ± 0.4 wt% ethanol. Figure 1 shows the contact angle measurement values ​​of examples A and B compared to a formulation without fibers (control). The hydrophobicity of example A and especially example B is clearly improved compared to the control values. Example B shows particularly high contact angles due to the hydrophobic coating of the cellulose fibers.

[0066] The contact angle measurements were performed using a Krüss Drop Shape Analyzer. For each sample, filter papers are thinly coated with the corresponding liquid patch. After drying to constant mass, the filter papers are placed horizontally on a block. Using a syringe, exactly one drop of water (2 pL) is applied to the film surface. A camera then determines the interior angle of the drop. The angle is measured at the level of the film surface. A larger angle indicates better hydrophobic properties of the film.

[0067] Figure 2 shows water vapor transmission rates (MVTR) of examples A and B compared to the blank value (measurement without sample) and a control (mean of six measurements / n=6).

[0068] Despite the addition of fiber material, examples A and B show surprisingly good and only slightly changed water vapor permeability compared to the control value.

[0069] The validated method DIN EN 13726-2 is used as a quantitative test for water vapor permeability. The MVTR value is determined in g / m 2*24h calculated, which indicates the "water vapor transmission rate." The formed film is weighed and clamped onto a thin, water-permeable Arnitel film in a 60 mL cup filled with water. The cups are inserted into the C360H device, and the weight loss from the starting point is measured after 6, 12, 18, and 24 hours at 37°C and 10% humidity. Since the cups are closed except for the top and the film is on top, the water can only evaporate through the film. The water vapor permeability is highly dependent on the film thickness and the applied film weight. A large weight difference implies good water vapor permeability. Figure 3 shows the bacterial permeability values ​​of examples A and B compared to the blank value and the control (n=1). Examples A and B, like the control, show no passage of mixed bacterial cultures after 1 and 6 hours.

[0070] As can be seen, the bacterial permeability in Example A and Example B is below the detection limit.

[0071] To measure bacterial permeability, the Gram-positive bacterial species Staphylococcus aureus (S. aureus) and Enterococcus hirae (E. hirae), as well as the Gram-negative bacteria Pseudomonas aeruginosa (PS) and Escherichia coli (E. coli), are stored at -70°C, and 10 μL of each is spread onto a TSA agar plate (consisting of casein peptone and soybean flour peptone) using an inoculating loop. These agar plates are left upside down for 24 hours to culture the bacteria. A small amount of each bacterial strain is added through the tip of an inoculating loop into 10 mL of dilution medium (NaCl and peptone in H2O). After shaking for 3 minutes, the optical density is measured at 600 nm and diluted to a value of 0.1 with the dilution medium. 1 mL of each of the four resulting bacterial solutions is mixed together (Appendix 30). After a subsequent 1:100 dilution, the bacterial mixture solution is ready.For this purpose, 100 μL of each of the four liquid plaster variants is applied twice to a stainless steel plate and left to dry completely. These two films are placed on a new agar plate for each liquid plaster variant, and 25 μL of the bacterial mixture is added to each film. For quantitative comparison, an additional 25 μL is added directly to the agar plate. This process is repeated twice for each liquid plaster variant and left to stand for one hour and six hours, respectively. The remaining bacterial suspension is then removed by pipetting, and the films are removed. The area beneath the plaster is punched out. This is also repeated for the area of ​​the directly applied agar. These punched-out agar pieces are each placed in 1 mL of rinsing medium and shaken in a 5 mL Eppi flask for 3 minutes.From the resulting supernatant, a 1:1000 dilution is made from the control sample and a 1:10 dilution is made from the normal samples in neutralization medium. The neutralization medium is intended to keep the bacterial count constant so that only those bacteria that have actually passed through the patch are detected. 10 μL of each solution is distributed onto a new agar plate and incubated for approximately 24 hours at 37°C. The bacterial colonies are then counted using an IIIL counter. An agar plate is divided into circles and a program counts the number of bacterial colonies in the outer circles. The colony count of the entire plate is then extrapolated using constant factors depending on the number of circles. The more bacterial colonies there are, the fewer circles are counted until a minimum number for extrapolation is reached.

[0072] Figure 4 shows the results of a subject study regarding perceived wearing comfort. Both Example A and Example B were predominantly perceived as very comfortable. Example A was not perceived as bothersome by any of the subjects, and Example B was perceived as bothersome by only two subjects.

[0073] For the study, 49 unbiased individuals were interviewed. The formulations were applied in thin films to the forearm using a 10 ml tube with a slanted applicator head. The subjects were asked about drying time, appearance, comfort, adhesion, peelability, and residue, among other things. Differences in age, gender, water contact, physical activity, and skin type were taken into account.

[0074] Figure 5a (photo of a wound closure film peeled from the skin) and Figure 5b (photo of a wound closure film according to the invention peeled from the skin) show that the viscose fibers have a positive effect on robustness only in specific concentration ranges (shown in Figure 5b). Figure 5a shows a wound closure film according to the prior art, which dries as a thin layer on the skin. This can only be peeled off the skin in small pieces. Figure 5b, on the other hand, shows a wound closure film according to the invention, which, due to its robustness provided by the viscose fibers, can be peeled off the skin in one piece.

Claims

Patent claims 1. Wound closure preparation comprising a) 0.3 - 14.7 wt% of at least one natural polymer, b) 0.3 - 4.2 wt% glycerol, c) 0.3 - 34.7 wt% of at least one vegetable oil, d) 0.1 - 13.7 wt% structuring fibers, e) one or more dermatologically acceptable solvents, wherein the wt% (percent by weight) refers to the entire wound closure preparation as a solution / suspension without optionally used propellant gases.

2. Wound closure preparation according to claim 1, characterized in that the natural polymer is selected from the group of cellulose, cellulose derivatives, in particular from the group of ethylcellulose, methylcellulose, hydroxypropyl methylcellulose, nitrocellulose, carboxymethylcellulose, gellan gum, xanthan gum, distarch phosphate, sclerotium gum.

3. Wound closure preparation according to claim 2, characterized in that the natural polymer is ethylcellulose.

4. Wound closure preparation according to at least one of the preceding claims, characterized in that the natural polymer has a molecular weight of 100,000 to 500,000 g / mol, in particular a molecular weight of 150,000 to 250,000 g / mol.

5. Wound closure preparation according to at least one of the preceding claims, characterized in that the vegetable oil is castor oil.

6. Wound closure preparation according to at least one of the preceding claims, characterized in that in addition to the content of castor oil, a second vegetable oil is also contained.

7. Wound closure preparation according to claim 6, characterized in that the vegetable oil other than castor oil is a sunflower oil.

8. Wound closure preparation according to at least one of the preceding claims, characterized in that the structuring fibers are viscose fibers or other fibers based on cellulose or cellulose derivatives, in particular viscose fibers, acetate fibers, bamboo fibers, lyocell fibers or modal fibers.

9. Wound closure preparation according to at least one of the preceding claims, characterized in that the structuring fibers have a length between 0.1 and 0.4 mm and a fineness of 0.9 to 20 dtex.

10. Wound closure preparation for application from tubes, syringes or drag piston dispensers comprising: a) 9.3 to 14.7% by weight of at least one ethylcellulose and / or ethylcellulose derivative, b) 11 to 21% by weight of castor oil, c) 6.3 to 13.7% by weight of sunflower oil, d) 1.8 to 4.2% by weight of glycerol, e) 4.7 to 13.7% by weight of viscose fibers, f) up to 66.9% by weight of one or more dermatologically acceptable solvents in which the preparation ingredients are dissolved g) optionally small amounts of pharmaceutical active ingredients and / or microbicides, the wt% (weight percent) specification relating to the entire wound closure preparation as a solution / suspension.

11. Wound closure preparation for application as an aerosol comprising: a) 0.8 to 4.2% by weight of cellulose and / or cellulose derivative, b) 1.2 to 15.8% by weight of castor oil, c) 0.4 to 1.6% by weight of glycerol, d) 0.4 to 2.1% by weight of viscose fibers, e) up to 97.2% by weight of one or more dermatologically acceptable solvents in which the preparation ingredients are dissolved, g) if necessary, small amounts of pharmaceutical active ingredients and / or microbicides, where the percentage by weight refers to the entire wound closure preparation as a solution / suspension.

12. Wound closure preparation for application as an aerosol comprising: a) 0.8 to 4.2% by weight of cellulose and / or cellulose derivative, b) 1.8 to 4.2% by weight of castor oil, c) 0.4 to 1.6% by weight of glycerol, d) 0.4 to 1.7% by weight of viscose fibers, e) up to 96.6% by weight of one or more dermatologically acceptable solvents in which the preparation ingredients are dissolved, g) if appropriate, small amounts of pharmaceutical active ingredients and / or microbicides, the wt% (weight percent) specification relating to the entire wound closure preparation as a solution / suspension.

13. Wound closure preparation for application as an aerosol comprising: a) 0.8 to 4.2% by weight of cellulose and / or cellulose derivative, b) 9.2 to 15.8% by weight of castor oil, c) 2.6 to 7.4% by weight of a vegetable oil other than castor oil, d) 0.4 to 1.6% by weight of glycerol, e) 0.4 to 1.7% by weight of viscose fibers, f) up to 86.6% by weight of one or more dermatologically acceptable solvents in which the preparation ingredients are dissolved, g) optionally small amounts of pharmaceutical active ingredients and / or microbicides, wherein the wt% (weight percent) refers to the entire wound closure preparation as a solution / suspension.

14. A wound closure preparation for application as an aerosol comprising: a) 9.3 to 14.7% by weight of cellulose and / or cellulose derivative, b) 11 to 21% by weight of castor oil, c) 6.3 to 13.7% by weight of a vegetable oil other than castor oil, d) 3.8 to 4.2% by weight of glycerol, e) 4.3 to 13.7% by weight of viscose fibers, f) up to 65.3% by weight of one or more dermatologically acceptable solvents in which the preparation ingredients are dissolved so that the solution is sufficiently viscous to prevent sedimentation of the fibers g) if necessary, small amounts of pharmaceutical active ingredients and / or microbicides, whereby the wt.% (percent by weight) refers to the entire wound closure preparation as a solution / suspension.

15. Wound closure preparation for application as an aerosol comprising a) 10.3 to 13.7% by weight of cellulose and / or cellulose derivative, b) 13.1 to 18.9% by weight of castor oil, c) 8.4 to 11.6% by weight of a vegetable oil other than castor oil, d) 2.3 to 3.7% by weight of glycerol, e) 7.5 to 10.5% by weight of viscose fibers, f) up to 68.4% by weight of one or more dermatologically acceptable solvents in which the preparation ingredients are dissolved so that the solution is highly viscous enough to prevent sedimentation of the fibers g) optionally small amounts of pharmaceutical active ingredients and / or microbicides, wherein the % by weight (percent by weight) refers to the entire wound closure preparation as a solution / suspension.

16. Wound closure preparation according to at least one of the preceding claims, characterized in that the cellulose and / or cellulose derivative is exclusively ethylcellulose.

17. Wound closure preparation according to at least one of the preceding claims, characterized in that the ratio of castor oil to glycerol is between 2.1 and 5, preferably from 4.3 to 4.

8.

18. Wound closure preparation according to at least one of the preceding claims, characterized in that the ratio of ethylcellulose to glycerol is 3.0 to 3.5, preferably 3.

3.

19. Wound closure preparation according to at least one of the preceding claims, characterized in that the ratio of ethylcellulose to viscose fibers is 0.8 to 2.4, preferably 1.2 to 1.

5.

20. Wound closure preparation according to at least one of the preceding claims, characterized in that the biocompatible solvent is selected from the group of alcohols.

21. Wound closure preparation according to at least one of the preceding claims, characterized in that the biocompatible solvent is ethanol.

22. Wound closure preparation according to at least one of the preceding claims, characterized in that the biocompatible solvent is ethyl acetate.

23. Wound closure preparation according to at least one of the preceding claims, characterized in that the cellulose and / or cellulose derivative has a molar mass of 150,000 to 250,000 g / mol.

24. Wound closure preparation according to at least one of the preceding claims, characterized in that the viscose fibers are hydrophobically coated.

25. Aerosol spray comprising a preparation according to at least one of the preceding claims, characterized in that it has the following contents: 1.9% ethylcellulose, 2.6% castor oil, 0.5% glycerol, 1.6% viscose fibers, 43.4% ethyl acetate dissolved in propane / butane 40 / 60.

26. Wound closure film formed from a preparation according to at least one of the preceding claims, characterized in that the preparation is applied to a wound and the solvent contained in the preparation has predominantly evaporated. I. Preparation according to at least one of the preceding claims, characterized in that, in addition to the main components, additional excipients are included, in particular pharmaceutical active ingredients that support wound healing and / or microbicides that counteract contamination, very particularly one or more excipients from the group consisting of antibacterial active ingredients, antimicrobial peptides, cationic polymers, octenidine, PHMB, wound-healing agents, mRNA, hyaluronic acid, anti-inflammatory agents, lidocaine, scar-reducing agents, silicones or silicone-like substances, pain-relieving agents, or cannabinoids.

Images